The US-based drug developer backed by Google's corporate venturing unit raises its latest funding round and buys a 21,500 square foot research facility.
Adimab, a US-based drug developer of yeast-based antibodies previously backed by Google’s corporate venturing unit, raised $13.8m on Monday, according to a filing with the Securities and Exchange Commission.
Adimab said the series F round was raised entirely from existing investors. Adimab added the company had bought a 21,500 square foot research facility at 7 Lucent Drive in Lebanon, New Hampshire, as the company’s headquarters.
Adimab said it has collaborated on more than 20 antibody discovery projects in the last…